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ABSTRACT 
Background: Hepatitis C is the most common chronic bloodborne infection in the United States. 
Currently in the U.S., there are more than an estimated 3 million people infected with hepatitis 
C. Here in Arizona, it is estimated that there may be as many as 80,000 Arizonans infected with 
hepatitis C (ADHS). Despite the availability of effective treatments for this chronic condition, 
treatment uptake remains low and is actually declining in the United States. This project 
investigates whether the knowledge, attitudes, and practices of Arizona providers regarding 
hepatitis C serve as a barrier to screening, diagnosis and care for HCV patients.  
Methods: This study employs a standard Knowledge, Attitudes, and Practices (KAP) survey that 
is forty questions long, with up to four additional conditional questions if participants answer 
the preceding question in a particular way. Questions were entered into Qualtrics, an online 
survey software tool, and distributed electronically using eight AZDHS email listservs and 
county-specific email listservs with licensed providers in Arizona. True or false knowledge 
questions were converted to a binary scale with “1” representing a correct answer and a “0” 
representing an incorrect answer. Multiple choice knowledge questions were analyzed 
qualitatively. Attitudes questions on a Likert scale were converted to a numerical score (1-5), 
with a higher number score being associated with a more empathetic response. Practices 
questions were either converted to a binary scale or left in their original format for further 
qualitative analysis. Statistical analysis was completed using a mixture of Univariate Logistic 
Regression, Fisher’s Exact tests, Wilcoxon Rank Sums, and Kruskal Wallis tests. 
Results: 77 responses were included in the final data analysis. Overall, providers demonstrated 
adequate knowledge regarding hepatitis C transmission, but an overall lack of knowledge about 
hepatitis C. Only 24% of participants answered all knowledge questions correctly. Participants 
felt more empathetic toward patients who contracted HCV through a blood transfusion 
(average Likert score = 4.39) compared to those who contracted HCV through using IV drugs 
(average Likert score = 3.95). 71% of providers feel that HCV screening falls under their scope of 
practice. Despite feeling confident in their knowledge of who to screen for HCV (average Likert 
score = 4.16), only 41% of respondents routinely screen for HCV. A majority of respondents 
  
preferred not to treat hepatitis C, mostly because they felt that was outside their scope of 
practice (53%). The most commonly cited reason overall for lack of treatment despite its 
potential benefit to patients was due to insurance coverage or cost concerns. 
Discussion: Our results indicate that AZ providers have inadequate knowledge of hepatitis C 
that drives insufficient clinical practices around screening patients, diagnosing new cases, and 
helping manage these patients on a regular basis. Though they deem HCV to be a public health 
threat, their unfamiliarity treatment modalities, coupled with inherent biases towards some of 
this patient population is in opposition to their perceptions regarding their own capability and 
comfort levels in caring for these patients, indicating a further gap in their awareness of this 
issue and the vulnerability that this patient population faces.   
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INTRODUCTION, SIGNIFICANCE & RATIONALE  
Hepatitis C is the most common chronic bloodborne infection in the United States 
(Alter, 1999). Currently, in the U.S., there are an estimated 2.5 million people infected with 
hepatitis C (Hofmesiter et al., 2018). Here in Arizona, it is estimated that there may be as many 
as 80,000 Arizonans infected with hepatitis C (ADHS). Hepatitis C is an acute or chronic liver 
disease caused by infection with the hepatitis C virus (HCV). Some patients infected with acute 
hepatitis C can clear the infection spontaneously, but as many as 85% of persons infected with 
HCV later develop chronic hepatitis C, which develops over several decades and may lead to 
additional complications and sequelae such as progressive hepatic fibrosis, cirrhosis, 
complications of liver failure, hepatocellular carcinoma, and death (Grebely et al., 2012). 
Hepatitis C is the leading cause of liver cancer and transplants, and here in the United States, 
HCV-related mortality has now surpassed HIV-related deaths, with over 15,000 individuals 
dying from HCV between 1999 to 2007 (Ly et al., 2012).  
As a bloodborne illness, HCV is commonly transmitted via percutaneous passage of 
infectious blood, as commonly seen with intravenous (IV) or injection drug use, blood donation 
or transfusion, needle stick injuries, or maternal transmission to a fetus. HCV may also be 
spread through sexual contact with an HCV-infected person or other health care procedures, 
though these are much more rare and inefficient means of transmission. IV drug use accounts 
for 60% of HCV transmission in the U.S (CDC 1998). Studies report one third of young injection 
drug users (IDUs) aged 18-30 years as infected and older IDUs having a higher prevalence of 
infection in the seventy to ninety percent range. Because IV drug use is the most common 
method of HCV transmission, HCV patients are also at risk for HIV/HCV coinfection, and 
coinfection is a major cause of morbidity and mortality in HIV-infected patients (Schaerer et al, 
2015).  
Once infected, it may take years for an individual to present with any symptoms, and 
consequently, many persons, particularly IV drug users, unknowingly transmit HCV. Recent 
estimates suggest that the HCV epidemic will continue to grow in size and will eventually result 
in 80 million infections globally (Bruggmann, Grebely, 2014). Given the increasing concern 
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regarding the growing number of HCV cases and the known outcomes for HCV patients, public 
health organizations and officials including groups like the World Health Organization (WHO) 
have acknowledged HCV as a public health problem and worked to implement strategies to try 
to help prevent the spread of HCV and better manage those who are known HCV-infected 
patients.  
Literature reviews reveal a number of studies that have examined the efficacy of various 
preventive interventions including needle syringe programs and medication-assisted treatment 
(MAT). Despite the demonstrated success of these programs, HCV infection remains a major 
public health concern as the number of cases continues to grow and other research shows that 
there is vast variation in the availability and uptake of HCV testing, screening, treatment, care, 
and support services (Jones et. al, 2013). Patients, healthcare providers, policy makers, and the 
public remain unaware of HCV and HCV literacy is also low among healthcare professionals and 
patients (Bruggman, Grebely, 2014); and clinical uptake of curative treatments now available 
such as direct-acting antivirals (DAAs) remains as low as 1-2% per year despite positive 
treatment responses, current guidelines for treatment, and high treatment willingness 
(Bruggman, Grebely, 2014). In the United States, in general, treatment uptake is declining, and 
studies predict that if this trend continues, only 14.5% of estimated liver-related deaths due to 
HCV between 2002-2030 will be prevented by therapy (Grebley, Dore, 2011). 
Additionally, physicians exhibit unsatisfactory knowledge and practices with regards to 
hepatitis C patients. Studies in Western Saudi Arabia, Iran, Canada, and the United States have 
illustrated that health care providers and physicians under report, under diagnose, under 
vaccinate, and undertreat hepatitis C. One study of family physicians in Canada demonstrated 
that many primary care providers (PCPs) believe HCV care to be outside of their scope of 
practice and consequently, they do not offer these types of services (Cox, et al, 2010). Another 
survey of family medicine and internal medicine physicians in the United States determined 
that both specialties showed significant gaps in knowledge regarding recommendations to 
vaccinate HCV-positive patients against hepatitis A and hepatitis B, though the gap was more 
statistically significant in family medicine physicians (Tenner, et al, 2012).  
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Rationale 
Though clinical research has shown the efficacy of certain preventive policies, treatment 
regimens, and screening guidelines, research on providers consistently reveals gaps in 
knowledge regarding the number of HCV patients remaining undiagnosed and untreated, why 
certain barriers to care exist, and how to overcome these barriers. A Knowledge, Attitudes and 
Practices (KAP) survey serves to elicit quantitative and qualitative information formatted in a 
questionnaire that can reveal misunderstandings or misconceptions regarding a certain topic 
(USAID, 2011). By targeting this kind of study towards providers in Arizona, we aimed to gain 
invaluable knowledge regarding the role that providers play in the general lack of HCV 
awareness, diagnosis, and treatment in our community that could result in initiatives and policy 
changes that will impact the future landscape of HCV in Arizona. As such, we sought to use this 
type of study to answer the question, “Do the knowledge, attitudes, and practices of Arizona 
providers regarding HCV and HCV patients inhibit their ability to diagnose, treat, and manage 
HCV patients?”  
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METHODS & MATERIALS  
Study Design 
This KAP survey was designed by the investigating medical student and the principle 
investigator. Survey questions were further reviewed by medical officers, county and state 
epidemiologists, and HCV subject matter experts at the Arizona Department of Health Services 
(ADHS) before distribution. Some survey questions were modeled after questions used in other 
KAP studies, while other questions were designed specifically to elicit particular information 
relevant to Arizona providers. The survey was forty questions long, with up to four additional 
conditional questions if participants answer the preceding question in a particular way (Table 
1). There were twelve demographic questions, ten knowledge questions, eight attitudes 
questions, and ten practices questions included in the final survey. Knowledge questions 
assessed factual knowledge regarding hepatitis C virus via true or false or “select all that apply,” 
type questions. Attitudes questions were ranked on a Likert scale (1 = Strongly disagree, 5 = 
Strongly agree). Practices questions were answered using multiple-choice options. Questions 
were entered into Qualtrics, an online survey software tool that served as the data collection 
tool. The survey was prefaced with a disclosure email to providers discussing the purpose of the 
study, what the data will be used for, and asking for their voluntary participation in the study.  
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Demographics 
1. What is your sex?  
2. How old are you?  
3. What is your medical degree?  
4. What is your specialty?  
a. Please specify which specialty within Internal Medicine 
5. Are you a currently practicing healthcare provider?  
6. In what county do you primarily practice?  
7. In what kind of health care setting do you primarily practice?  
8. How many patients do you see per week on average?  
9. What percentage of your patient population was born between 1945-1965?  
10. What percentage of your patients are insured?  
11. Of those who are insured, what percentage of your patients are on AHCCCS (Arizona State Medicaid)?  
12. What percentage of your patients do you think are using intravenous (IV) drugs?  
  
Knowledge 
1. There is a vaccine for Hepatitis C. 
2. Intravenous (IV) drug users should be screened for hepatitis C. 
3. Patients born between 1945-1965 should be screened for hepatitis C.  
4. Hepatitis C can become a chronic infection.  
5. There are drugs available that can cure hepatitis C.  
6. Hepatitis C is associated with an increased risk of liver cancer.  
7. A person may be infected with hepatitis C virus and have no symptoms.  
8. A patient who has had hepatitis C cannot be reinfected because they are immune.  
9. The presence of hepatitis C RNA is diagnostic of an HCV infection.  
10. Hepatitis C can be transmitted through the following ways (please select all that apply). 
  
Attitudes 
1. I feel sorry for people who contracted HCV through a blood transfusion 
2. I feel sorry for people who contracted HCV through using intravenous (IV) drugs 
3. Screening for HCV falls under my scope of practice.  
4. I do not screen certain patients for HCV because they would not be eligible for treatment.  
5. I feel confident in my knowledge of who to screen for HCV.  
6. I feel comfortable treating and managing a HCV patient myself.  
7. I believe that hepatitis C is a significant public health threat.  
8. I feel confident in my ability to interpret HCV screening or test results.  
  
Practices 
1. Do you routinely screen patients for HCV?  
a. Which patients do you screen for HCV? 
2. Do you have systematic reminders in your electronic medical record (EMR) system to flag when to 
screen a patient for HCV?  
3. Do you see any patients who have hepatitis C?  
4. Do you treat any newly diagnosed HCV cases yourself?  
5. Do you refer newly diagnosed HCV patients to specialists?  
6. Do you have patients with HCV that would benefit from treatment but are currently untreated?  
a. What are barriers to treatment for these patients?  
7. Do you counsel HCV-positive patients about preventing transmission to other people?  
8. Do you counsel HCV-positive patients about their prognosis and provide any recommendations for 
minimizing morbidity and mortality?  
9. Do you order additional tests after a patient has a positive HCV screening result?  
10. Would you like to treat HCV in your office?  
a. Why would you prefer to not manage HCV in your office?  
  
Table 1: Final KAP Study Questions 
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Recruitment 
The survey was distributed electronically using eight ADHS email listservs and county-
specific email listservs with licensed providers in Arizona (Table 2), reaching approximately 
5,000 providers. The survey remained open for 3 months and was distributed to the same 
listservs periodically throughout that time frame.  
Statistical Analysis 
 At its conclusion, 102 study participants had begun the survey. In order to prevent 
skewing the data or creating bias, we only analyzed data from surveys that had been completed 
in their entirety. Consequently, final analysis included 77 respondents. True or false knowledge 
questions were converted to a binary scale with “1” representing a correct answer, then 
analyzed. Multiple choice knowledge questions were analyzed qualitatively. Attitudes questions 
were converted to a numerical score (1-5), with a higher number score representing a more 
empathetic response. Practices questions were either converted to a binary scale or left in their 
original format for further qualitative analysis. 
 Statistical analysis was completed using a mixture of Univariate Logistic Regression, 
Fisher’s Exact tests, Wilcoxon Rank Sums, and Kruskal Wallis tests.  
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Table 2: Email Listservs Utilized to Distribute Survey 
 
 
  
1. Arizona Academy of Family Physicians (AzAFP) 
2. Arizona Alliance for Community Health Centers (AACHC) 
3. Arizona Department of Health Services Mobile Application  
4. Arizona Infectious Disease Society (ArIDS) 
5. Arizona Medical Association (ArMA) 
6. Arizona Nurse Practitioner Council (CAzNAP) 
7. Health Action Network (HAN) 
8. Maricopa County Medical Society (MCMS) 
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RESULTS 
Demographics 
 Of the 77 participants included in the final analysis, 31 were NPs or RNs, while 46 
participants were MDs or DOs. 35 men and 42 women completed the study. A majority of 
participants were middle-age or older providers (aged fifty-one or older). There were 26 family 
medicine providers, 11 inpatient internal medicine providers, 5 gastroenterology/hepatology 
providers and a smaller number of other specialty providers who participated. 61 participants 
lived in an urban county (Maricopa or Pima Counties), and 49 participants practice in 
outpatient, non-urgent clinical settings (Table 3).  
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Table 3: Participant Demographics 
  
Variables N=77 
Provider’s Age, Years (n, %) 
< 40 
41-50 
51-60 
>60 
 
18 (23.4) 
14 (18.2) 
24 (31.2) 
21 (27.3) 
Gender (Male, %) 
Gender (Female, %) 
35 (45.5) 
42 (55.5) 
Medical Degree (n, %) 
NP/RN 
MD/DO 
 
31 (40.3) 
46 (59.7) 
Specialty (n, %) 
Primary Care 
Non-Primary Care/Surgical 
 
39 (50.7) 
38 (49.4) 
Country Where Practice (n, %) 
Maricopa 
Pima 
Other 
 
47 (61.0) 
14 (18.2) 
16 (20.8) 
Practice Setting (n, %) 
Inpatient 
Outpatient 
Other 
 
18 (23.4) 
45 (58.4) 
14 (18.2) 
Number of Patients per Week (n, %) 
< 20 
21 - 40 
41 – 60 
>60 
 
20 (25.9) 
20 (25.9) 
10 (13.0) 
27 (35.1) 
Patients Born between 1945-1965 (n, %) 
0-25% 
26-50% 
>50% 
 
17 (22.1) 
37 (28.1) 
23 (29.9) 
Patients Insured (n, %) 
< 50% 
51 – 75% 
76-100% 
 
16 (20.8) 
17 (22.1) 
44 (57.1) 
Patients on AHCCCS (n, %) 
< 50% 
51- 75% 
76-100% 
 
52 (67.5) 
17 (22.1) 
8 (10.4) 
Patients on IV drugs (n, %) 
< 10% 
>10% 
 
62 (80.5) 
15 (19.5) 
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Knowledge 
Overall, a majority of respondents correctly identified that HCV is predominantly a 
bloodborne disease, and several also correctly identified that hepatitis C may also be 
transmitted sexually or perinatally. However, almost ¼ of respondents (n = 19) incorrectly 
identified saliva as a mechanism of transmission, and five respondents identified mosquitos as a 
mechanism of transmission. Only 18 respondents correctly identified all mechanisms of 
transmission correctly (Figure 1).  
Nineteen percent of respondents incorrectly answered that the presence of HCV RNA is 
not diagnostic of an HCV infection. 14% of respondents incorrectly answered that patients 
cannot be reinfected with HCV because they are able to develop immunity. 11% of respondents 
incorrectly answered that there is a vaccine for hepatitis C. 9% incorrectly answered that there 
are not drugs available to treat hepatitis C.  
 In general, MD/DOs answered knowledge questions correctly more often than NP/RNs. 
There was a statistically significant difference in the number of MD/DOs that correctly 
answered that HCV can be transmitted via blood transfusions and perinatally compared to 
NP/RN participants (p < 0.01 and p < 0.05 respectively). Only 24% of participants answered all 
knowledge questions correctly and only 22% of outpatient providers answered all knowledge 
questions correctly. There was a statically significant difference in the number of providers in 
Maricopa who correctly identified that HCV can be transmitted via sexual contact and via 
unsterile tattooing compared to providers in other rural counties (not including Pima) (p < 
0.001).  
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Figure 1: Participant Knowledge About HCV 
*Indicates a true statement 
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Provider Knowledge About HCV (n=77)
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Attitudes 
Attitudes questions were generally divided into two categories for analysis: 
“confidence” and “empathy”. When asked about levels of empathy for HCV patients who were 
infected through a blood transfusion, respondents on average agreed that they felt sorry for 
those patients (average Likert score = 4.39). However, respondents felt less empathetic when 
asked about HCV patients who were infected through IV drug use (average Likert score = 3.95). 
Only 4 respondents when asked about empathy for IV drug users disagreed that they felt sorry 
for these patients, and they were family medicine, internal medicine and surgical practitioners.   
Seventy-one percent of participants “Agree” or “Strongly Agree” that screening for HCV 
falls under their scope of practice, while only 12% of participants, including 100% of EM 
participants, outright disagreed that screening for HCV falls under their scope of practice. 
Participants felt confident about who to screen for HCV (average Likert score = 4.16), but were 
less confident about interpreting HCV screening tests (average Likert score = 3.89), and were 
not at all confident about treating or managing these patients on their own (average Likert 
score = 2.45) There was a statistically significant difference in how confident primary care 
providers felt in their knowledge of who to screen for HCV compared to non-primary care or 
surgical providers (p < 0.05). 
For questions unrelated to empathy or confidence, participants reported that they 
believe HCV is a significant public health issue (average Likert score = 4.49).  
A comparison between overall empathy and confidence versus clinical practices such as 
screening, counseling, and treating patients revealed a statistically significant relationship 
between those that engage in each of those clinical practices and overall confidence (p < 
0.001), but no statistically significant relationship between those same participants and overall 
empathy. There also was no statistically significant relationship between overall empathy or 
confidence and those participants able to correctly answer all knowledge questions or all 
transmission questions correctly.  
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Practices 
Screening & Diagnosis 
Screening practices varied widely across respondents. While 71% of respondents noted 
that they believe screening for HCV falls in under their scope of practice, only 42% of 
respondents, including only 53% of outpatient participants, endorse routinely screening 
patients for HCV, and only 46% of respondents noted that they order further follow-up testing 
after a positive screening result. When analyzed demographically, there was a statistically 
significant difference in the number of primary care providers who routinely screen patients for 
HCV compared to non-primary care or surgical providers, and in the number of providers in 
Maricopa who routinely screen patients compared to those in Pima (p < 0.05 respectively). 
Further, there was a statistically significant difference in the number of MD/DOs, primary care 
providers, and outpatient providers who ordered follow-up tests after a positive screening 
result compared to their counterparts (p < 0.05 respectively).  
However, of those who do routinely screen patients, a majority of study participants 
knew to screen patients in all categories asked about (Figure 2). Of concern, 35% of family 
medicine providers do not routinely screen the children of HCV mothers. Only 15% of 
respondents noted that they have systematic reminders in their electronic medical records to 
flag when a patient should be screened for hepatitis C.  
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Figure 2: Participant Screening Practices 
*Indicates a screening practice not necessarily recommended by the CDC 
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Treatment 
Almost all participants see patients who have hepatitis C (92%), but a majority of 
participants (almost 66%) replied that they almost always refer an HCV-positive patient to a 
specialist, rather than treating the patient themselves; and only 22% of respondents answered 
that they would like to treat HCV in their office. For those respondents who preferred to not 
manage HCV in their office (n=62), 53%, including 42% of outpatient providers, said it was 
because they felt that treatment of HCV is outside of the scope of their practice (Table 4). Upon 
further analysis, there was a statistically significant difference in the number of MD/DOs and 
non-primary care or surgical providers who believe treatment to be outside of their scope of 
practice compared to NP/RNs and primary care providers (p < 0.01 respectively). Interestingly, 
only 28% of providers feel they have insufficient clinical knowledge to treat HCV patients. While 
only 8 participants identified that they felt these patients were difficult and time consuming to 
manage, those with higher proportions of Medicaid patients and those with patient populations 
containing a higher percentage of IV drug users were more likely to answer this way.  
Fifty-three percent of respondents answered that they have patients with HCV that 
would benefit from treatment but who are currently untreated. The most commonly cited 
reason overall for lack of treatment despite its potential benefit to patients was due to 
insurance coverage or cost concerns (Table 5). When analyzed demographically, there was a 
statistically significant difference in the number of patients who would benefit from treatment 
amongst MD/DO participants versus NP/RN participants (p < 0.05) and amongst providers with 
fewer than 10% of their patient population as IV drug users versus more than 10% (p < 0.05).  
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Reasons for not wanting to treat 
Answers Number of responses (n=62) 
Treatment of HCV is outside of the scope of 
my practice. 33 
I feel I have insufficient clinical knowledge 
about how to manage HCV.  22 
I believe these are difficult to manage 
patients and I do not have time to manage 
them adequately. 
8 
I have concerns about the cost that I could 
incur by treating HCV-positive patients. 9 
Inappropriate clinical setting to treat HCV 
(psych clinic, wound clinic, etc.). 5 
It's not a personal passion of mine.  1 
Table 4: Reasons for Not Wanting to Treat HCV 
 
 
  
17 
 
Barriers to Treatment 
Answers Number of Responses (n=42) 
Patient's insurance will not cover 
treatment/patient is uninsured/cost of 
treatment is prohibitive. 
35 
Patient is not interested in treatment 
(concerns about side effect profile, lack of 
knowledge, etc.). 
24 
Patient is noncompliant with treatment or 
continues high-risk behaviors that would 
disqualify them from treatment. 
24 
I would not recommend treatment because 
of patient factors (age, current health status, 
etc.). 
3 
Difficulty getting an appointment with 
specialists. 1 
Table 5: Barriers to Treatment per Study Participants 
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Counseling 
When asked whether they routinely counseled HCV-positive patients on how to prevent 
transmission to other people, only 38 providers said that they almost always counsel their 
patients, while 21 responded that they almost never counseled their patients on preventing 
transmission. A multivariate analysis determined a statistically significant relationship between 
those who do counsel patients about preventing transmission and those who were able to 
answer all knowledge questions correctly (p < 0.05). 
When asked about counseling patients regarding minimizing morbidity and mortality, 
practices varied widely across respondents, though most participants counseled patients on at 
least one topic (Figure 3). Only 8% of participants did not counsel patients regarding ways to 
reduce morbidity and mortality at all, and there was a statistically significant difference in the 
number of females that did not counsel patients at all compared to the number of males (p < 
0.05). The most common topic to counsel patients on was avoiding alcohol consumption and 
the least common to counsel on using fresh or clean needles. Interestingly, there was a 
statistically significant difference in the number of NP/RNs that counseled patients on avoiding 
alcohol and using only clean or fresh needles compared to MD/DOs (p < 0.05 respectively). 
There was also a statistically significant difference in the number of primary care providers that 
counseled patients in almost every topic except for avoiding acetaminophen containing drugs 
compared to no-primary care and surgical providers (p <0.05).  
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Figure 3: Participant Counseling Practices 
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DISCUSSION 
 Literature reviews reveal a lack of available studies regarding physician knowledge and 
attitudes towards HCV. Of those that do exist, only a few have been completed here in the 
United States and none have been completed regarding Hepatitis C in Arizona.  
Numerous studies have tried to determine the barriers to HCV treatment, which are 
extensive, and include lack of provider expertise in HCV and limited access to specialists 
(Morrill, et al, 2005). However, one study in the Veterans Affairs system determined that the 
strongest independent predictor of HCV treatment was attending one visit with an HCV 
specialist (Kramer, et al, 2011). Another study found that patients in Australia who had sought 
HCV care from a trained provider were more likely to receive treatment (Grebely, et al, 2011). 
While these studies also noted significant structural barriers to HCV assessment and care 
including limited knowledge of testing locations, limited accessibility of testing results and 
treatment, and long waiting lists for treatment, they indicate that improving physician 
knowledge and accessibility could be an avenue for potential solutions. 
Knowledge 
Overall, Arizona providers demonstrated an adequate baseline knowledge regarding 
HCV and its means of transmission. While only a small minority of participants correctly 
answered all knowledge questions, most respondents were able to correctly answer the 
commonly known or asked questions regarding HCV. While our results do identify some gaps in 
knowledge, these gaps are higher level questions including that hepatitis C can be transmitted 
sexually and perinatally.  
 Other questions that participants failed to answer correctly consistently included that 
there is a cure for HCV and that the presence of HCV RNA is diagnostic of an infection, which is 
concerning. Interestingly, in spite of this, a majority of respondents believe they have sufficient 
knowledge about hepatitis C, which likely indicates that providers are overestimating their 
capabilities and may also demonstrate that providers have a difficult time admitting when they 
do not know something or when they are wrong.  
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 It is not surprising that MD/DOs performed better on the knowledge questions 
compared to NP/RNs as the level of training required for MD/DOs tends to be higher and more 
comprehensive.  
Attitudes 
Participants demonstrated a marked bias towards HCV-positive patients who were also 
IV drug users, highlighting the continued bias many providers have against certain patient 
populations that engage in these behaviors.  
The gradation in attitudes towards screening, diagnosis, and treatment of HCV is 
understandable and follows the natural progression of HCV management over the past several 
decades. Screening for HCV has commonly fallen under primary care’s responsibilities, while 
treatment of HCV has commonly fallen under the specialist’s scope of practice. This was likely 
largely driven by the fact that HCV previously was incurable, and the drugs used to manage HCV 
were complex with difficult side effect profiles. Currently, treatment of HCV is much more 
straightforward as the medications are much more tolerable and only need to be used for a 
relatively short period of time for successful treatment. However, these treatment modalities 
are still relatively new and were only developed within the last ten years. We believe that the 
attitudes identified in our study toward comfort with diagnosing and treating HCV reflect the 
recent changes to HCV management over the past few years and will likely change given more 
time to become familiar with the available treatment medications. That said, we also are 
unsurprised by the fact that those with strong clinical practices regarding HCV also feel more 
overall confidence, as they are likely less concerned about causing a patient harm if via 
misdiagnosing them or incorrectly treating them if they are more comfortable with the required 
knowledge to do so.   
Screening & Diagnosis 
While many participants agreed that screening for HCV falls under their scope of 
practice and most participants knew which patient populations to screen, a minority actually 
perform routine screening, possibly indicating that providers do not prioritize screening for HCV 
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compared to other routine health maintenance screening or they lack adequate time with 
patients to consider screening them for all recommended health maintenance issues. It is also 
possible that once again, providers are overestimating their capabilities and clinical practices. 
Further, participants rarely ordered follow-up testing after a positive screening result, implying 
a fundamental lack of understanding of the pathogenesis of HCV infection. Of those that do 
order follow-up testing, we would expect MD/DOs, primary care providers, and outpatient 
providers to be more familiar with which follow-up tests to order and how given their expected 
wider knowledge base about HCV and stronger screening practices due to the inherent nature 
of their clinical practice. While the statistically significant difference in the practices amongst 
these provider groups is expected and encouraging, our results indicate that screening practices 
are insufficient across all groups included in this study, particularly amongst outpatient 
providers who should be familiar with screening guidelines and accustomed to performing 
these types of screening exams, but still are only doing so a minority of the time. 
Given that so few participants have systematic reminders in their EMRs and so many 
participants do not consistently screen, it is possible that working with healthcare systems and 
EMRs to insert such reminders when patients fall within certain identified demographics may 
help improve clinical practice.  
Treatment 
Scope of practice remains a large barrier to care for these patients. The gap between 
those who do not treat HCV and those who refer patients to specialists indicates that some 
providers truly do not feel responsible for helping treat HCV and perhaps even indicates a larger 
attitude that providers do not bear responsibility for patients outside of their direct care. 
Further, we conclude that the effort to shift treatment and management of HCV from specialty 
care to outpatient care has either been unsuccessful or is still in the early stages of this process. 
This may be because outpatient providers already feel overburdened by the scope of the care 
they must provide to patients. We also conclude that the difference in how MD/DOs feel about 
treatment for HCV being within their scope of practice compared to NP/RNs may reflect the 
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status of our healthcare system, in which MD/DOs are typically specialized or very 
subspecialized and cannot switch specialties easily.   
Contrary to what we expected, providers did not express that they did not want to treat 
HCV because they felt they had insufficient knowledge regarding it or because they felt like 
these patients were too medically complicated to take on, with the exception of providers who 
had patient panels containing higher percentages of Medicaid patients or IV drug users. 
However, it was clear from our results that the cost of care and treatment continues to be a 
large barrier for patients.  
Counseling 
Counseling practices were a further gap identified in the care of the patients. A minority 
of respondents identified that they regularly counsel their HCV patients on how to prevent 
transmission to others and on how to minimize morbidity and mortality. Of those that did, only 
primary care providers regularly counseled patients about multiple ways to minimize morbidity 
and mortality, likely as counseling typically falls under a primary care provider’s scope of 
practice. The lack of counseling about reducing transmission may indicate that these providers 
either do not consider HCV to be a highly communicable disease the way they consider HIV to 
be, or they are primarily concerned with individual patient outcomes relevant to their patient 
panel rather than population health or the well-being of those who do not fall directly under 
their care. Additionally, the least common topic to counsel patients on was using only clean or 
fresh needles, indicating an inability or lack of desire to address this topic and a possible 
inherent bias toward these patients.  
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CONCLUSION & FUTURE CONSIDERATIONS 
The data generated through this survey is unique and helps determine Arizona 
providers’ current capacity to diagnose and treat hepatitis C. Ultimately, we conclude that while 
AZ providers consider HCV to be a significant public health issue, they also have inadequate 
knowledge of hepatitis C that drives insufficient clinical practices around screening patients for 
hepatitis C, diagnosing new cases of hepatitis C, and helping manage these patients on a regular 
basis. Though outpatient and primary care providers typically had stronger practices in this 
study compared to their non-primary care, surgical, or inpatient counterparts, a minority 
demonstrated adequate performance in all categories. Their unfamiliarity with the topic and 
treatment modalities, coupled with inherent biases towards some of this patient population is 
in direct opposition to their perceptions regarding their own capability and comfort levels in 
caring for these patients, indicating a further gap in their awareness of this issue and the 
vulnerability that this patient population faces.  
We further conclude that hepatitis C patients in Arizona continue to face tremendous 
barriers to treatment due to concerns over the cost of treatment or insurance coverage and the 
fact that most providers do not believe that treating hepatitis C falls under their scope of 
practice, a fact that has been demonstrated in other studies as well. The push to transition 
diagnosis and treatment of HCV from specialty services to primary care has yet to take full 
effect and offers a further opportunity for us to continue educating primary care and outpatient 
providers about the new treatment modalities for HCV in order to better offer access to care 
for these patients.  
In addition to identifying several general trends, we have also been able to identify 
specific gaps in knowledge, attitudes, and practices that interfere with clinical practice around 
these patients. These specific gaps may be easily addressed moving forward with increased 
educational campaigns, specifically around all the ways in which HCV can be transmitted, and 
counseling practices to reduce transmission and morbidity and mortality.  
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 While we originally may have hypothesized that provider confidence in their familiarity 
and practices with HCV would enhance their clinical practice with HCV patients, we also 
hypothesized that a lack of empathy for this patient population would inhibit their clinical 
practice. Per our results, we found no significant relationships between overall provider 
empathy for HCV patients and their clinical practices, perhaps reflecting a limitation of this 
study due to its small sample size or population sample.   
This study has several limitations. While it is a much larger study and the first study of 
this type conducted in Arizona, the study should be repeated for validity. Further, there is an 
inherent level of selection bias as the study population was self-selecting. We tried to minimize 
levels of bias by only analyzing fully completed questionnaires and those completed by 
providers who are still currently practicing. However, there were several respondents included 
in the final analysis who did not practice in clinical settings or specialties that inherently lend 
themselves to care of hepatitis C patients.  
We hope to use this data to create targeted interventions for some of the gaps 
identified in this study. Further studies are needed to better determine the impact of specialty 
care on patient outcomes in this population, the level of access to specialty care for these 
patients, and the demographics of this patient population. Additionally, it would be interesting 
to further study the referral process that occurs when a patient screens positive for HCV to 
better understand the ways in which we can continue to transition diagnosis and care of HCV 
from specialty services to primary care services.  
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